ReShape Lifesciences Inc. SEC Filings

Vyome Holdings, Inc. (ticker HIND) filed an Initial Statement of Beneficial Ownership (Form 3) for Robert Dickey IV, who is identified as the company’s Chief Financial Officer and a director. The filing reports the qualifying event date as 08/15/2025 and is signed on 09/11/2025. The form states explicitly that no securities are beneficially owned by the reporting person at the time of filing, meaning Mr. Dickey disclosed no direct or indirect ownership of the issuer’s equity or derivative securities in this submission.

Vyome Holdings, Inc. reported that it has completed its previously announced merger in which Raider Lifesciences Inc., a subsidiary of the company, merged into Vyome Therapeutics, Inc., with Vyome surviving as a subsidiary. Following the merger, the registrant was renamed Vyome Holdings, Inc. and Vyome continues as Vyome Therapeutics, Inc.

The company is providing Vyome’s financial statements for the quarter ended June 30, 2025, Vyome’s Management’s Discussion and Analysis for that quarter, and unaudited pro forma condensed combined financial statements as exhibits. This information is being made available so it can be incorporated by reference into Vyome Holdings’ shelf registration statement on Form S-3.

Vyome Holdings, Inc. reported that it amended its equity distribution agreement with Maxim Group to increase the size of its at-the-market common stock offering capacity from $3,420,926 to $12,000,000, allowing shares to be sold from time to time under its existing Form S-3 shelf registration.

The company also changed its independent registered public accounting firm, dismissing Haskell & White LLP and appointing Kreit & Chiu CPA LLP for the fiscal year ending December 31, 2025, with the change approved by the audit committee and board. Vyome states there were no disagreements with Haskell on accounting or auditing matters, though Haskell’s report for the year ended December 31, 2024 included an explanatory paragraph about substantial doubt regarding Vyome’s ability to continue as a going concern and referenced material weaknesses in internal control over financial reporting.

Vyome Holdings, Inc. is updating its at-the-market offering program to allow issuance and sale of up to approximately $12,000,000 of its common stock through Maxim Group LLC under an amended Equity Distribution Agreement. These primary offerings are made under its existing Form S-3 shelf registration and are limited by Form S-3 General Instruction I.B.6, which caps sales to no more than one-third of the public float in any 12-month period.

As of August 20, 2025, Vyome’s public float was about $57.37 million, based on 3,658,613 non-affiliate shares at $15.68 per share, and it has already sold roughly $7.07 million of securities under this rule in the prior 12 months, leaving additional capacity. The shares may be sold on Nasdaq Capital Market, where the stock trades under the symbol “HIND,” with Maxim earning up to 3.0% of gross proceeds as sales compensation.

Vyome Holdings, Inc. completed its previously announced merger in which Raider Lifesciences, a subsidiary of ReShape Lifesciences, merged into Vyome Therapeutics, Inc., making Vyome a subsidiary and prompting a corporate name change to Vyome Holdings, Inc. Common and preferred shares of Vyome were converted into ReShape common stock based on a predetermined exchange ratio, and Vyome equity awards were converted into awards over Vyome Holdings shares.

The company also closed an asset sale, transferring ReShape’s assets (excluding cash) to Biorad for $2.25 million in cash, with Biorad assuming substantially all ReShape liabilities subject to working capital adjustments. Immediately after the merger, Vyome Holdings sold 529,137 common shares at $11.02 per share and Vyome Limited sold 999 shares at $937.14 per share under a put-call arrangement.

On August 15, 2025, the company effected a 1-for-4 reverse stock split to support compliance with Nasdaq’s minimum bid price, and its shares continued trading on The Nasdaq Capital Market under the name Vyome Holdings, Inc. and symbol HIND. In connection with the merger, the prior directors and key executives resigned, a new six-member board and committees were installed, Venkateswarlu Nelabhotla became Chief Executive Officer, and Robert Dickey was engaged as Interim Chief Financial Officer under a one-year, $15,000-per-month agreement.

ReShape Lifesciences received an amended Schedule 13G from L1 Capital Global Opportunities Master Fund, Ltd. reporting beneficial ownership of 7,862 shares of common stock underlying warrants, representing 0.33% of the class based on 2,385,960 shares outstanding after the offering referenced in the issuer's June 9, 2025 prospectus supplement. The filing states the shares are held by the Cayman Islands entity and clarifies that David Feldman and Joel Arber are directors of the reporting fund and may be deemed to beneficially own the securities but disclaim such ownership for other purposes. The filing affirms the position is not intended to influence control of the issuer.

ReShape Lifesciences (RSLS) reported constrained liquidity and multiple financings during the six months ended June 30, 2025. The company had approximately $4.1 million in cash and $1.4 million of accounts receivable at June 30, 2025, and disclosed substantial doubt about its ability to continue as a going concern for more than 12 months. During the period the company completed several financings: a February 2025 Security Purchase Agreement that generated approximately $4.8 million net, an at-the-market offering in June 2025 that raised about $3.8 million net, and a June 9, 2025 public offering that produced about $2.4 million net. Warrants issued in February 2025 were exercised on a cashless basis in April 2025, resulting in issuance of 576,416 shares to investors and 28,825 shares to the placement agent. The company completed a 1-for-58 reverse stock split and disclosed an exclusive license agreement with Biorad and an anticipated asset sale with $2.25 million subject to adjustments. The company is evaluating new accounting guidance on expense disaggregation and income tax disclosures and reported ongoing equity-based compensation activity.

ReShape Lifesciences Schedule 13G/A filed by CVI Investments, Inc. and Heights Capital Management, Inc. reports that the reporting persons beneficially own 0 shares (0%) of the company’s common stock. Heights Capital is identified as the investment manager to CVI and may be deemed to have voting and dispositive power over shares held by CVI, although both entities expressly disclaim beneficial ownership except for any pecuniary interest. The filing notes ownership is below 5% and certifies the securities were not acquired to change or influence control of the issuer.

ReShape Lifesciences Schedule 13G/A discloses that Ayrton Capital LLC, Alto Opportunity Master Fund, SPC - Segregated Master Portfolio B, and Waqas Khatri each report beneficial ownership of 80 shares of common stock of the issuer. The 80-share position is described as 8 shares held plus 72 shares issuable on exercise of warrants, and the warrant-related issuable shares are subject to a 9.99% beneficial ownership blocker. The holdings are reported as of June 30, 2025.

The filing uses a class base of 2,385,960 shares (1,331,356 outstanding plus 1,054,604 shares sold in a recent offering) and reports that each reporting person represents 0.003% of the class. The reporting parties include a Cayman Islands fund managed by Ayrton Capital and Waqas Khatri as managing member; signatures certify the securities were acquired and are held in the ordinary course of business and not to change or influence control.